Compounds and methods for treating inflammation
US-2022054581-A1 · Feb 24, 2022 · US
Soluble lipidated ligand agents for treating eye inflammation
US12060397B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12060397-B2 |
| Application number | US-202117525169-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 12, 2021 |
| Priority date | Apr 12, 2013 |
| Publication date | Aug 13, 2024 |
| Grant date | Aug 13, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of treating inflammation in the eye, the method comprising administering to the eye of a subject in need thereof a soluble lipidated ligand agent that has the following structure: wherein each of the Y, S, and A amino acids are D-amino acids, and wherein Tic represents (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. 2. The method of claim 1 , wherein the soluble lipidated ligand agent is formulated as a pharmaceutical composition comprising the soluble lipidated ligand agent and a pharmaceutically acceptable carrier. 3. The method of claim 1 , wherein the soluble lipidated ligand agent is administered at an effective dose at an administration interval such that at least one symptom or feature of inflammation is reduced in intensity, severity, duration, or frequency or has delayed onset. 4. The method of claim 1 , wherein the soluble lipidated ligand entity is administered daily, twice a week, once a week, once every two weeks, once every three weeks, once a month, or at a variable interval. 5. The method of claim 1 , wherein the soluble lipidated ligand entity is administered topically. 6. A method of treating inflammation in the eye, the method comprising administering to the eye of a subject in need thereof a soluble lipidated ligand agent that has the following structure: (SEQ ID NO.: 11), wherein one or more of the Y, S, and A amino acids are D-amino acids, and wherein Tic represents (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Assignees
Inventors
Classifications
on expression patterns · CPC title
having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title
having 5 to 11 amino acids · CPC title
acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation · CPC title
Assays, e.g. immunoassays or enzyme assays, involving lipids · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12060397B2 cover?
- The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.
- Who is the assignee on this patent?
- Tufts Medical Center, Tufts College, On Target Therapeutics Llc
- What technology area does this patent fall under?
- Primary CPC classification G01N33/92. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).